Comparative Pharmacology
Head-to-head clinical analysis: METRETON versus METRO I V.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRETON versus METRO I V.
METRETON vs METRO I.V.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
8 hours (range 6-10 hours) in adults; prolonged to 12-24 hours in hepatic impairment.
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Renal: 60-80% unchanged; fecal: 6-15% (includes metabolites); biliary: minor contribution.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)